Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil for Aura and Migraine Induction
NCT02795351Phase 1Completed
- Sponsor
- Herlev Hospital
- Start
- Jun 2015
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP-001 in migraine with aura (2 arms), sponsored by Herlev Hospital. Primary endpoint: Aura and migraine like headache induction at 14 hours. Started Jun 2015; status: completed.
02
Drugs
ASP-001
03
Conditions
migraine with aura
Beyond the preview
Go deeper on NCT02795351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02795351.